Nanovaccines have emerged as promising alternatives or complements to conventional
cancer treatments. Despite the progresses, specific co‐delivery of antigen and adjuvant to …

Among approaches of current cancer immunotherapy, a dendritic cell (DC)-targeted vaccine
based on nanotechnology could be a promising way to efficiently induce potent immune …

Efficient delivery of vaccines to dendritic cells (DCs) is critical for inducing sufficient immune
response and realizing effective cancer immunotherapy. In the past decade, researchers …

Efficient cancer vaccines not only require the co-delivery of potent antigens and highly
immunostimulatory adjuvants to initiate robust tumor-specific host immune response but also …

Codelivery nanovaccines of antigens and adjuvants have achieved positive therapy for
cancer immunotherapy. The insufficient immunogenicity of these vaccines leads to the …

For efficient cancer vaccines, the antitumor function largely relies on cytotoxic T cells, whose
activation can be effectively induced via antigen-encoding mRNA, making mRNA-based …

Tumor vaccines for cancer prevention and treatment have attracted tremendous interests in
the area of cancer immunotherapy in recent years. In this work, we present a strategy to …

The antitumor efficacy of tumor vaccines is often limited by weak T cell responses and poor
activated T cells infiltration. Herein, we reported a novel synergistic strategy to …

The protumoral and immunosuppressive tumor microenvironments greatly limit the antitumor
immune responses of nanoparticles for cancer immunotherapy. Here, the intrinsic …

Dendritic cells (DCs) present exogenous antigens on major histocompatibility complex
(MHC) class I molecules, thereby activating CD8+ T cells, contributing to tumor elimination …